Printer Friendly

COMPANY INFORMATION
Advanced Proteome Therapeutics Corporation Suite 113, 650 Albany St Boston, MA, United States 02118 Tel: (617) 638-0340 Fax: (617) 638-0341 Contact Name Alexander Krantz Industry Biotechnology		Key Executives Alexander Krantz, CEO Kenneth C. Phillippe, CFO Develops and commercializes a technology platform that is intended to use advanced protein modification technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties.
FP ADVISOR COVERAGE Advanced Proteome Therapeutics Corporation • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX-VEN/APC $0.27 $0.50 $0.18 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 21,850 n.a. US$-0.02 Apr. 30/09 45.95% 12.43% 55.18% $19,171
ANNUAL FINANCIALS Periods ended: 12m July 31/08 12m July 31/07 12m July 31/06 US$000s US$000s US$000s Net income (1,135) (1,896) (137) Total assets 2,599 1,616 310 US$ US$ US$ Earnings per share* (0.02) (0.04) (0.01) % % % Return on equity (73.42) (337.07) n.m.   * Common

COMPANY NEWS

Results for 'Advanced Proteome Therapeutics Corporation' from past 30 days: No hits. (Links are to articles.)